Some breast cancerpatients on hormone therapy experience hairloss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hairloss, and considering alternatives like topical finasteride.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hairloss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hairloss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
The conversation is about a user sharing their progress with hairloss treatment using 2.5 mg oral finasteride and a 5% minoxidil spray, encouraging others to stay consistent. The user noticed results in mid-August and has not experienced side effects, despite the high dosage of finasteride.
Hairloss prevention and regrowth regimen includes finasteride, oral minoxidil, stemoxydine, hair growth serum, derma rolling, and ketocanazole shampoo. Users discuss efficacy, safety, and personal experiences with treatments.